Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Carcinoma, Hepatocellular
- Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation
- Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma
- A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
- Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
- A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
- Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)
- A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
- HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
- Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
- Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
- TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
- TIPS Plus Cadonilimab in Advanced HCC With Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
- H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
- HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
- HACI Combined With Durvalumab, Tremelimumab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
- A Phase II Study of PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
- SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
- Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
- Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
- A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
- Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
- Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
- Radiofrequency Ablation in Combination With Lenvatinib and Sintilimab
- A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
- AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
- Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
- Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
- Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation
- Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
- Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
- TACE-HAIC+Atezolizumab+Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial
- The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation
- Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer
- Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
- A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
- SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
- Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC
- SIRT With Tremelimumab and Durvalumab for Resectable HCC
- Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
- Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
- Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatocellular Carcinoma.
- Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma
- AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
- Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
- Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti- PD-(L)1 Antibody on the Treatment of uHCC
- Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
- A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
- Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy
- Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma
- Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
- HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
- Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
- Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy
- Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
- Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
- Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
- Lenvatinib Plus Sintilimab vs. Lenvatinib for Advanced HCC Treated With TACE
- KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
- A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
- A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Hepatocellular Carcinoma
- Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
- Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
- HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
- Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma
- AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
- Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
- Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
- Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
- TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
- TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
- Phase 1b Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable Hepatocellular Carcinoma
- Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
- Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
- LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial
- Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
- Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
- Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment
- Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
- A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene
- HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
- HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
- HAIC Combined With Targeted Therapy and Immunotherapy as Down-stage Therapy of LT
- TACE With Dicycloplatin(TP21) in Unresectable HCC
- Neoadjuvant Anti-PD1 in HCC
- Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib
- Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
- Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
- Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
- A Phase 2, Open-Label Study of ABSK-011 Plus Atezolizumab to Assess Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy in Patients With Advanced or Unresectable Hepatocellular Carcinoma
- Durvalumab and Tremelimumab in Resectable HCC
- Phase 1b/2 Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
- T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
- A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
- mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
- Phase Ⅱ/III Studies to Investigate the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Hepatocellular Carcinoma (HCC)
- A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
- Efficacy and Safety of T+A+RAD in HCC
- A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
- Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
- Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
- A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Primary Gastric Cancer and Colorectal Cancer (CRC)
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
- A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
- Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
- Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation
- NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
- TACE Combined With Penpulimab and Anlotinib for Advanced HCC
- IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
- A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
- Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors
- Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
- Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
- A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
- A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
- Study of ADI-PEG 20 Versus Placebo in Subjects With Genotype WWOX-GG, Unresectable HCC
- Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
- HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
- Postoperative Adjuvant Therapy of HCC Based on PD-1
- Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
- Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study
- HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
- Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
- Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
- A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
- Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma
- Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
- DEB-TACE+HAIC vs. HAIC for Large HCC
- CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
- A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
- TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
- Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
- Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
- HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
- Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
- VG161 in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
- Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
- TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
- A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
- Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
- A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
- Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
- Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
- Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
- Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
- Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma
- GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
- Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
- Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
- Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)in the First-line Treatment of Unresectable Hepatocellular Carcinoma
- HAIC Combine With Lenvatinib and Camrelizumab for Advanced HCC With PVTT
- Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
- Donafenib Plus Sintilimab for Advanced HCC
- Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
- Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio
- Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)
- HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
- Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
- The Efficacy and Safety of Retreatment With HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
- Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study
- Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
- Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative
- TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
- Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol)
- Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma
- Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy
- A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
- Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
- Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
- Hepatocellular Carcinoma Imaging Using PSMA PET/CT
- Role of DEB-TACE Versus c-TACE in Treatment of HCC
- SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
- A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
- Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)
- Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
- Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
- A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
- A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
- Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC
- TheraSphere With and Without Durvalumab and Tremelimumab for HCC
- Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
- Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
- HMBD-001 in Advanced HER3 Positive Solid Tumours
- Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
- Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
- Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
- GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
- The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC
- A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
- Immunotherapy for Advanced Liver Cancer
- HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Advanced Unresectable HCC
- IMC001 for Clinical Research on Advanced Digestive System Malignancies
- Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
- Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Recurrent Hepatocellular Carcinoma
- 18F-DCFPyL PET/CT in Hepatocellular Carcinoma
- Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
- to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve
- Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
- Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
- The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
- Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
- TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
- TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
- A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
- A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
- TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors
- Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
- Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
- TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02)
- DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
- Adjuvant Therapy With Anlotinib for HCC
- Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab Versus HAIC Alone for Advanced Hepatocellular Carcinoma
- Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC
- Low Dose ICG for Biliary Tract and Tumor Imaging
- SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
- Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
- SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
- Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
- Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
- TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
- SBRT + Atezolizumab + Bevacizumab in Resectable HCC
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
- A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
- Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
- cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
- The Effect of Ultrasound-guided Erector Spinae Plane Block on Postoperative Analgesia in Radiofrequency Ablation Therapy
- Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
- A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
- Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
- A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
- Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
- PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial
- Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial
- Carelizumab Combined With Regorafenib in the Treatment of HCC(CARE-2020)
- The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
- Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
- Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma
- TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study
- Regorafenib and Nivolumab Combined Versus TACE in Intermediate-Stage HCC Beyond Up-to-7 (RENOTACE)
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Intra-tumor Injection of Drug-eluting Microspheres
- Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors
- 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
- Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma
- A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With BI 754091 to Patients With Advanced Solid Tumors Having the B7-H6 Marker
- Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
- A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
- Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
- Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC
- A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
- Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Safety, Tolerability and Anti-tumour Activity Study of MTL-CEBPA Plus Sorafenib
- Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
- Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
- Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial
- Safety, Tolerability, PK, Anti-Tumor Activity of STP705 Injected IT in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Thera
- HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial
- Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
- IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
- Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
- HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
- Perioperative Therapy for Hepatocellular Carcinoma
- Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma
- RFA Combined With PD-1 in HCC: Phase II Study
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
- ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
- Study of INCB086550 in Select Solid Tumors
- HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
- HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
- Tislelizumab Neo-adjuvant Treatment for Resectable RHCC
- SynOV1.1 Intratumoral Injection Study
- Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC
- Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
- Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients
- KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
- TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
- TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
- TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC
- TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
- Cabozantinib in Hepatocellular Carcinoma
- Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
- Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
- An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
- The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
- SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
- TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
- NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
- Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
- HepATocellular Cancer Hcv Therapy Study
- The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
- Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
- Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer
- Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma
- Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis
- Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design
- A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells
- Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)
- The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
- A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to Lenvatinib Treatment
- Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
- TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
- A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
- Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
- Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
- Optimization for Regorafenib in HCC
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
- A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
- A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function
- A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
- Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
- Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
- To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
- Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
- Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma
- Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
- Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients
- A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
- Ib Study of the Efficacy and Safety of IBI310 Combined With Sintilimab in Advanced Hepatocellular Carcinoma
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
- A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
- SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
- Study of SRF388 in Patients With Advanced Solid Tumors
- Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
- Itacitinib in Advanced Hepatocellular Carcinoma
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Me
- ATG-008 Combined With Toripalimab in Advanced Solid Tumors
- A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC
- Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
- Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
- Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
- GEN2 Directed Cancer Immunotherapy Trial
- Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma
- PSMA PET/MRI or PSMA PET/CT for Evaluation of Hepatocellular Carcinoma
- Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma
- TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma
- A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
- SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma
- Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
- Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis
- Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
- Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter
- Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
- DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
- Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation
- Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
- P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
- DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
- Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
- Longitudinal Immune-phenotyping of HCC Following MK-3475
- Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
- Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
- MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
- Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
- The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer
- A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
- A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma
- RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
- Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma
- Atezolizumab Plus Bevacizumab With HCC and HBV Infection
- The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
- Neoadjuvant Therapy for Hepatocellular Carcinoma
- Erlotinib for Hepatocellular Carcinoma Chemoprevention
- A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
- Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
- Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
- Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT
- Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
- Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)
- Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
- Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
- Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
- HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
- Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
- Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC
- Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
- Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- A Study of LY3435151 in Participants With Solid Tumors
- T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
- Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
- Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
- Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
- TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
- The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)
- The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
- Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Nivolumab Combined With BMS-986253 in HCC Patients
- Effectiveness of Drug Eluting TACE in Primary HCC
- Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
- HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
- Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
- Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
- High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
- RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
- Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
- Neoadjuvant TACE With or Without RT for HCC Involving PVTT
- SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
- SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
- Study of Adoptive Transfer of iNKT Cells Combined With TACE to Treat Advanced HCC
- A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
- Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC
- YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
- TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma
- Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection
- Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma
- 68 Ga PSMA PET/MRI for Hepatocellular Carcinoma
- 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3
- Albumin for Hepatocellular Carcinoma
- A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients
- A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
- A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
- Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant
- Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
- Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
- A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
- Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
- Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
- Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
- A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
- Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma
- TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
- Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
- ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
- Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
- Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
- HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Thermal Ablation Followed by Immunotherapy for HCC
- Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma
- Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
- Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
- FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
- Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
- TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
- A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
- Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy With ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy
- A Study of PTX-9908 Injection for Non-resectable HCC With TACE
- HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
- Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
- HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
- A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
- A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
- The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma
- Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
- Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
- TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
- Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
- A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
- HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
- HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
- A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
- Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
- HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
- Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy
- Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors
- IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
- Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Participants With Advanced PD-L1 Positive Malignancies
- Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
- Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
- Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
- An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
- A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
- Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma
- Radiotherapy/Apatinib for Adjuvant Treatment of HCC Patients receIved Curative reSEction With Microvascular Invasion
- Irradiation Stent Placement Plus TACE for HCC and PVTT
- Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
- SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
- Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
- A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
- APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
- IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
- The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
- A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
- [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
- DKN-01 Inhibition in Advanced Liver Cancer
- CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
- Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation
- Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
- This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
- Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
- TACE-HAIC vs. HAIC for Potentially Resectable HCC
- A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
- CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
- SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
- Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
- Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
- Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
- The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus
- A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
- Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis
- Expanding Phase III Study of Tyroserleutide for Injection
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
- Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma
- The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients
- Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
- Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
- Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
- Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
- Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)
- Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
- Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
- HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
- A Phase II Study of PTS100 in Primary HCC Patients
- TCR-engineered T Cells in Solid Tumors: IMA202-101
- Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
- An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
- Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- Pembrolizumab in Hepatocellular Carcinoma
- A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
- Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
- The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma
- Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
- Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
- Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
- Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment
- Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
- A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
- Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
- SBRT or TACE for Advanced HCC
- Pembrolizumab as Neoadjuvant Treatment in HCC
- FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
- A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
- Study of Pembrolizumab and Radiotherapy in Liver Cancer
- Study of GNS561 in Patients With Liver Cancer
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
- Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging
- Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
- Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization
- Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
- A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
- Treatment of Advanced Hepatocellular Carcinoma
- Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge
- Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma
- Treatment of Intermediate-stage Hepatocellular Carcinoma
- TACE Emulsion Versus Suspension
- Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection
- Combination of TATE and PD-1 Inhibitor in Liver Cancer
- Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
- Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
- Meclizine for Hepatocellular Carcinoma
- The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
- Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
- Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
- Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)
- Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
- Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
- The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction
- Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
- Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
- IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients
- Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
- Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
- The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Contr
- The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
- Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science
- Celebrex and Metformin for Postoperative Hepatocellular Carcinoma
- Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
- Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
- Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
- Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
- Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
- Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver
- TATE Versus TACE in Intermediate Stage HCC
- An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
- A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
- Novel Gallium Imaging in Hepatocellular Carcinoma
- Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
- Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
- Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
- Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
- Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
- A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
- Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
- Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
- Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
- Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment
- Paediatric Hepatic International Tumour Trial
- Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis
- A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
- A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
- Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
- Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
- Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
- The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.
- Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil
- Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma
- HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
- Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis
- Circulating Tumor Cells and Tumor DNA in HCC and NET
- Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
- Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
- Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC
- RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma
- Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
- DAA in the Risk of Recurrence After Curative Treatment of HCC
- A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
- Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
- Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
- Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
- Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer
- A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
- Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma
- Randomized Phase II Trial of Chemoembolization and Sorafenib
- Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)
- Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
- FDGal PET/CT to Detect Hepatocellular Carcinoma
- Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
- Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
- A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
- HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
- Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
- A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
- Chemoembolization for Hepatocellular Carcinoma
- The Combination Effect of Statin Plus Metformin on Relapse-free
- The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC
- Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
- A Study of Anlotinib in Patients With Hepatocellular Carcinoma
- Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma
- Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
- TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
- Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma
- Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
- A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
- Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
- Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection
- Contrast-enhanced Ultrasound Evaluation of Chemoembolization
- Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
- Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)
- Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
- Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection
- Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
- A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
- Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
- Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC
- Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
- First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
- Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
- A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
- Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
- Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
- Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
- [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
- An Open Study Assessing the Safety and Tolerability of U3-1784
- Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) and / or Microvascular Invasion
- CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab in Subjects With Advanced GI Tumors (Keynote 596)
- Metformin Plus Sorafenib for Advanced HCC
- Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
- A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection
- Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
- Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
- Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
- Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
- Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
- TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
- HCC Patient Preferences in Japan
- Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma
- Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
- Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
- Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation
- MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
- A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer
- An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
- MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
- A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
- A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
- Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
- p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
- Trial of TRC105 and Sorafenib in Patients With HCC
- Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial Chemoembolization
- 11C-acetate for Treatment Response After Radiotherapy for HCC
- Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
- Prophylactic Antibiotics Before RFA for HCC
- Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
- TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
- A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
- Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
- Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
- Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.
- LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
- Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients
- Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
- Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
- Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
- Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
- A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcin
- Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC
- Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
- HR Combined With FOLFOX4 for HCC With PVTT
- Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
- Adjuvant Therapies for Patients With HCC and MVI
- HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC
- A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
- RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC
- Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma
- Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
- A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
- A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
- Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma
- Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
- Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
- Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
- Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
- Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
- Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy
- A Study of rSIFN-co in Subjects With Advanced Solid Tumors
- A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
- A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
- Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
- Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC
- Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
- FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
- Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
- Primary Prevention Hepatocellular Carcinoma by Metformin
- Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
- Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)
- Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
- Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma
- Combine TACE and RFA Versus TACE Alone for HCC With PVTT
- Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
- A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
- Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
- Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
- A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
- Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
- Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
- Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma
- A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma
- Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
- A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
- A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
- A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
- Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
- The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
- A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma
- Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma
- Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
- Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
- Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
- Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
- A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
- Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
- Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
- LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
- Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
- PROLIFICA - West African Treatment Cohort for Hepatitis B
- Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
- Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
- c-Met Second-Line Hepatocellular Carcinoma
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
- Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
- Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
- Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
- A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma
- Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
- Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
- A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
- 3-Tesla MRI Response to TACE in HCC (Liver Cancer)
- Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
- Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
- A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
- Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study
- Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
- Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
- Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
- Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
- The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
- Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
- 24hr Imaging Of HCC After EOVIST
- T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
- TACE as an Adjuvant Therapy After Hepatectomy for HCC
- Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
- Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
- The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma
- A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
- Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery
- Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma
- Urea Cream Treatment Sorafenib-Associated HSFR in HCC
- Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib
- Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
- Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
- Preoperative Pain Control in Liver Surgery Patients
- Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
- Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
- A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurr
- Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
- Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
- Sorafenib Chemoembolization Evaluation Controlled Trial
- Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
- Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion
- Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC
- A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
- Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
- Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
- Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
- TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
- Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
- Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
- Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion
- Tremelimumab With Chemoembolization or Ablation for Liver Cancer
- HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
- Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
- Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
- A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
- Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
- P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.
- Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
- Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
- DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
- A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
- Sorafenib + mFOLFOX for Hepatocellular Carcinoma
- Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
- Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
- A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
- Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
- Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
- A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
- SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Sorafenib for Residue Disease After Resection With Curative Intent
- Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
- A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
- Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
- A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
- Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
- TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
- the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
- Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase
- Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
- Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
- A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
- Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
- STA-9090 in Patients With Advanced Hepatocellular Cancer
- Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
- Study of ARQ 197 in Hepatocellular Carcinoma (HCC)
- Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
- Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery
- Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)
- Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
- Hepatic Xenetix-CT Perfusion
- Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
- Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
- Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
- TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
- Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
- The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List
- Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis
- Temsirolimus as Second-line Therapy in HCC
- Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
- A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
- Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma
- Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
- Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
- Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
- S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)
- Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
- Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
- A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
- Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
- Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma
- Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
- MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
- Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
- Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
- Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
- Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma
- Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
- SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma
- Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
- Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
- A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)
- A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
- Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma
- Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
- Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma
- A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
- MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
- Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma
- Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
- Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
- Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
- Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
- A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
- PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
- Use of N-Acetylcysteine During Liver Procurement
- Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)
- Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
- Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma
- TRC105 for Liver Cancer That Has Not Responded to Sorafenib
- Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)
- Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
- Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
- Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
- Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
- Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
- A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
- Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma
- Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
- A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
- Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)
- Sorafenib and TRC105 in Hepatocellular Cancer
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
- Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
- Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
- Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
- E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
- Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy
- Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
- Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
- A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC
- Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
- Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
- Hepatocellular Carcinoma (HCC)_Torisel_
- A Study of LY2157299 in Participants With Hepatocellular Carcinoma
- Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
- MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
- Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy
- A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
- Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)
- A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the E
- Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
- Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
- Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
- Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
- ABT-888 and Temozolomide for Liver Cancer
- Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
- Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
- A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
- GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
- Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
- Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
- Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
- Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
- Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
- Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
- Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
- Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids
- Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
- Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
- Siliphos in Advanced Hepatocellular Carcinoma
- 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
- Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
- Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)
- Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
- Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
- A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
- Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
- Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
- Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma
- Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
- Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
- Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
- Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
- The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma
- Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
- Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas
- Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
- CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
- Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
- AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
- Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
- Regulatory Post Marketing Surveillance Study on Nexavar®
- Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
- Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
- Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
- Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
- Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
- Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
- Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
- Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
- Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
- Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
- Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
- Study of Pegylated Human Recombinant Arginase for Liver Cancer
- A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
- A Study to Assess PV-10 Chemoablation of Cancer of the Liver
- Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
- Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
- Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
- TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)
- Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
- Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
- Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
- Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
- Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life
- 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
- Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
- Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy
- Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
- Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
- Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
- A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
- Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
- Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
- An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
- XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
- LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
- Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
- A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
- Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer
- SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
- First Line Hepato Cellular Carcinoma (HCC)
- A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
- Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients
- Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
- Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
- Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
- Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
- Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
- The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma
- Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
- Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
- Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma
- Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
- The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma
- Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection
- Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
- A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
- A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection
- Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence
- Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
- Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
- Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)
- Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma
- Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
- INSIGHT - Post Marketing Surveillance
- Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
- A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
- Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
- Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma
- Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
- Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma
- Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
- Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
- A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
- Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
- Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
- Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)
- Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
- Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
- A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
- Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
- Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
- Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
- Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
- Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
- Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
- Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
- Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
- Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
- Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients
- Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
- Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
- Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)
- TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
- Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
- Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
- Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
- Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
- Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
- Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
- Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
- Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria
- Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
- Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma
- UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma
- Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
- RAD001 in Advanced Hepatocellular Carcinoma
- Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
- GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
- Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
- Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
- Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study
- A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
- Sorafenib With TACE to Treat Hepatocellular Carcinoma
- Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients
- Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
- Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients
- Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)
- Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)
- Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma
- Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
- A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma
- A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
- A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
- AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
- Proton Therapy and Bevacizumab for Primary Liver Tumors
- A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
- A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
- Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
- Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
- Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
- A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
- A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
- Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
- SU011248 in Advanced Hepatocellular Carcinoma
- Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
- A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
- A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
- Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)
- Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
- Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
- Celecoxib and Erlotinib in Treating Patients With Liver Cancer
- Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
- Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
- Oxaliplatin in Unresectable Hepatocellular Carcinoma
- Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma
- Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
- Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
- Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
- Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
- Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
- PI-88 in Hepatocellular Carcinoma After Hepatectomy
- An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
- Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
- Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
- Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC
- Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
- A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
- Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors
- A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
- Bevacizumab in Advanced Hepatocellular Carcinoma
- Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
- Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
- Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma
- Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
- Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
- Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
- Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
- Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
- A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
- Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
- A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
- SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer
- Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
- Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
- A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
- A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care
- Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
- Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
- Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
- TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
- Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
- Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
- Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
- Prevention of Recurrent Hepatitis B After Liver Transplantation
- Epirubicin and Thalidomide in Treating Patients With Liver Cancer
- Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
- T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
- Testing of ADI-PEG in Hepatocellular Carcinoma
- Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads
- T900607 in Treating Patients With Unresectable Liver Cancer
- Oxaliplatin in Treating Patients With Liver Cancer
- Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
- Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
- Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
- Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
- Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
- A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
- Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.
- Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
- Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
- Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
- BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
- Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
- Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate
- Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
- Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
- Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- DX-8951f in Treating Patients With Liver Cancer
- Chemotherapy in Treating Children With Liver Cancer
- Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
- Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
- Tamoxifen in Treating Patients With Primary Liver Cancer